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ABSTRACT  
 
In rectal cancer, total mesorectal excision (TME), including surgery with dissection outside the 
mesorectal fascia, together with pre-operative radiotherapy improves survival. An educational effort 
on TME improved results in rectal cancer in Stockholm in the 1990’s. The Stockholm Colon Cancer 
Project (SCCP) was an educational project on the management on colon cancer, launched in 2004, 
introducing Complete Mesocolic Excision (CME). CME is described as an en-bloc resection of a large 
part of the mesocolon with preservation of the mesocolic fascia and a proximal vascular ligature. The 
term ‘CME’ is relatively novel although the concept has been relevant since long ago. A partly 
synonymous term is D3-surgery, referring to the resection of centrally disposed lymph nodes. The 
overall aim of this thesis was to evaluate the effect of the introduction of CME on short- and long term 
outcome for patients with colon cancer. In Paper I all patients operated for right-sided colon cancer in 
the Stockholm area, between 1996 and 2009 were divided into three time periods. The number of 
analyzed lymph nodes increased significantly over the study period. The proportion of patients having 
less than 12 lymph nodes analyzed in the specimen decreased from 77.1% to 18.3% (p<0.001). 
Metastatic index (MI) (in lymph node positive patients) was 0.40 in period 1 and 2, compared to 0.25 
in period 3 (p<0.001). In Paper II survival for patients diagnosed with right sided colon cancer before 
(2001-2003, n=819) and after (2006-2008, n=897) SCCP was studied. The proportion of patients 
having a tumor resection was larger in the earlier group, 96.6% compared to 91.2% the latter group 
(p<0.001). There were a larger proportion of patients having emergency tumor resection in the earlier 
time period and there was a significantly higher proportion of R0 resection in the latter group. The 
crude three year disease free survival among patients in TNM stage I-III who had their tumor resected 
was also significantly higher in the latter time period, 71.5% compared to 64.6% (p=0.006). In Paper 
III patients operated for right sided colon cancer between 2004 and 2012 was studied in a case-control 
study. Cases were patients that died within 90 days of surgery or had an emergency re-operation. Two 
controls per case were matched for sex, age-interval, TNM-stage and emergency surgery. Exposure 
was CME determined from surgical reports. The reports were classified as “CME” or “no CME” 
according to pre-defined criteria. The Odds Ratio (OR) for postoperative death or re-operation was 
0.75 (95% CI: 0.50-1.13)(p=0.17) for CME surgery compared to no CME surgery, suggesting CME is 
not associated with short term morbidity or mortality. 
In Paper IV, all patients, electively operated for right sided colon cancer (stage I-III) in Stockholm 
between 2008 and 2012 were studied in a cohort study (n=1171). CME-exposure was determined in 
a similar way as in paper III. Five year relapse-free survival (RFS) was 73.6% in the “CME” group 
vs 63.5% in patients classified as “no CME”. The multivariable adjusted model showed a 
significantly improved RFS for the “CME” group, Hazard Ratio (HR)=0.74 (95% CI: 0.58-0.94, 
p=0.014).   
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BACKGROUND 
Basic physiology and anatomy 
the colon is a major part of the gastrointestinal tract. Its functions include re-uptake of fluids 
and electrolytes as well as storage and elimination of rest products of food. The colon is 
embryological derived from the midgut and the hindgut. At rest, 4.3% of cardiac output 
flows to the large intestine1. The vascular supply of the colon is, thru different vessels, 
derived from the abdominal part of the aorta. The superior mesenteric artery (SMA) departs 
from the aorta in the upper part of the abdomen. The SMA supplies the small bowel but is 
also the origin of the vessels supplying the ascending colon and the proximal two thirds of 
the transverse colon. The ileocolic artery (ICA) supplies the terminal ileum and the caecum. 
The right colic artery (RCA) supplies the ascending colon but is subject to anatomical 
variations, it is actually only present in 33-63% of individuals2-4. Thus, in many individuals 
the ascending colon and the right flexure are supplied from branches from the ICA and from 
the middle colic artery (MCA). The MCA arises from the SMA and supplies the proximal 
two thirds of the transverse colon. The distal part of the transverse colon and the descending 
colon are supplied from the left colic artery (LCA), which is a branch from the inferior 
mesenteric artery (IMA), in turn the last major branch of the aorta before it divides into the 
iliac arteries. The sigmoid colon has its arterial supply from the sigmoidal arteries which are 
branches from the superior rectal artery (SRA), the continuation of the IMA after its 
division from the LCA. The venous drainage follows the corresponding arteries. However, 
the venous drainage from the right colon has some complex anatomical features, important 
for surgical oncology as well as patient-safe surgery. Lymphatic drainage from the colon 
follows the vascular pattern. 
Common definitions of the boundary between the colon and the rectum are the level of the 
sacral promontory or within 15 cm from the anal verge.   
Epidemiology 
Colorectal cancer (CRC) is a common disease in man. Globally it’s the third most common 
cancer, causing approximatively 600 000 deaths yearly. The incidence varies regionally with 
Western Europe as an area of high incidence, together with Australia, New Zealand and North 
America. The lifetime risk of acquiring colon- or rectal cancer is in the United States between 
5 and 6%. High incidence of CRC seems to be associated with “western lifestyle” and is 
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rising in many low- and middle-income countries whereas in highly developed countries rates 
are stabilizing or decreasing5-7. 
In Sweden, CRC is the third most common form of cancer, after prostate- and breast cancer. 
Between 2007 and 2011 there were in Sweden approximatively 6000 new cases of CRC 
yearly. About two thirds of them were colon cancer. The incidence rate of CRC in Sweden 
was 69/100 000 in 2015. In Sweden the age-standardized incidence of colon cancer has 
increased in recent decades, while rectal cancer has had an almost unchanged incidence. CRC 
is an uncommon disease in young people. Less than 5% of patients are under the age of 50 at 
the time of diagnosis, with a similar pattern for colon- and rectal cancer8. However, in non-
Hispanic white people in the United States an increase in CRC has been noted, mostly in 
distal colon cancer and rectal cancer9. 
Etiology 
It is a common accepted view that CRC is developed from neoplastic adenomas in the 
bowel mucosa. This is supported by the fact that colonoscopic polypectomy leads to a 
lower-than-expected incidence of CRC10, 11. The molecular pathway in the transformation 
from polyp/adenoma to cancer is complex. The steps required for the development of 
cancer often involve the mutational activation of an oncogene coupled with the loss of 
several genes that normally suppress tumor genesis12. 
Riskfactors 
Many separate risk factors have been studied for determining a connection to the 
development of CRC. Smoking, a risk factor for numerous causes of illness but often not 
primarily mentioned when discussing CRC, has in two large meta-analyses been shown to 
be a risk factor for developing CRC13, 14. Alcohol consumption has in a study from 2004 
been associated with a moderate, and dose dependent, risk-elevation for developing CRC15, 
supported by later studies14. High intake of red and processed meat increases the risk of 
CRC14, 16-18. Obesity has also been found to be a risk factor for CRC14. Recently, a Danish 
study also noted that high body mass index (BMI) or being tall in childhood is associated 
with increased risk for colon, but not rectal, cancer19. An Israeli study showed that being 
overweight (85th weight-percentile) in adolescence was associated with an increased risk of 
subsequent colon cancer, whereas only obesity (95th weight-percentile)was associated with 
rectal cancer20. Diabetes, both type 1 and 2, is a risk factor for developing CRC21, 22. Also, 
sedentary behavior is a risk factor for colon, but not rectal, cancer23. 
Compared to the general population, and to patients undergoing appendectomy, non-
surgical treatment for appendicitis is associated with an elevated risk for right sided colon 
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cancer, even after exclusion of patients diagnosed with colon cancer the first 12 months 
after the appendicitis diagnosis24, 25. 
Factors reducing the risk of colorectal cancer 
Long term use of acetylsalicylic acid (Aspirin) has been shown to reduce the risk of 
developing colorectal adenomas as well as CRC26-28. Physical activity is strongly associated 
with a reduced risk of colon cancer (CC)29. Oral calcium supplementation has in a 
randomized controlled trial (RCT) been shown to reduce the risk of cancer disease in 
general, although the numbers were too small for CRC specifically30. In animal 
experimental studies, Vitamin D deficiency has been associated with cancer development 
and growth31. In population based studies, intake of calcium and dairy products has been 
shown having a protective effect against colon cancer18, 32, 33. There are studies showing that 
a high intake of dietary fibers reduces the risk of CRC34, 35 proposedly by reducing 
constipation and bowel transit time, while other studies have not been able to confirm that 
connection36. The risk-reduction seen in some studies associated with high fiber intake may 
be attributed to intake of fruit and vegetables35, 37. Coffee consumption seems to be 
associated with a lower risk of CRC38.  
Hereditary colorectal cancer  
The absolute majority of cases of CRC are so called sporadic. Hereditary CRC occurring 
due to known mutations and defects in certain genes accounts for about 5% of all cases of 
CRC39, 40. 
Familial Adenomatous Polyposis (FAP) is an autosomal-dominant disorder that is associated 
with mutations in the APC tumor suppressor gene. It has an approximate prevalence of 1 in 
10,000 births and is characterized by the presence of hundreds or even thousands of colonic 
adenomatous polyps. Polyps occur at young age, often before 20. If the colon and rectum are 
not removed, the lifetime risk of CRC is >90%, often occurring before the age of 40. FAP 
accounts for less than 1% of cases of CRC39, 41. 
Lynch Syndrome, synonymous with Hereditary Nonpolyposis Colorectal Cancer (HNPCC), 
is the most common hereditary CRC syndrome and is caused by inherited mutations 
affecting any of four DNA mismatch repair (MMR) genes. It accounts approximately for 2% 
to 3% of all CRCs. It is also an autosomal dominant, inherited disorder. The average patient 
age at cancer diagnosis is 45 years. Individuals with HNPCC have a high occurrence of 
synchronous and proximal colonic malignancies. Lynch syndrome also entails elevated risk 
for developing other malignancies, especially endometrial, but also ovarian, gastric, small 
intestine, or renal cancer42-44. 
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Screening 
Screening is testing for disease in apparently healthy people in order to detect disease in an 
early stage, enabling successful treatment. Different methods of screening for CRC includes 
Guaiac based faecal occult blood test (gFOBT), Faecal immunochemical tests (FIT) and 
detection of stool DNA. In the case of a positive test the patient is offered diagnostics, often 
a colonoscopy. Randomized studies have shown a possibility for lowering CRC-deaths by 
screening measures in a population45, 46. In 2003 the Council of the European Union issued 
recommendations for CRC screening and in Stockholm, Sweden, screening started in 2008 
for individuals aged 60-69. Of those that during the first five years of screening program 
participated with Fecal Occult Blood Test (FOBT) 1.8% underwent screening-colonoscopy 
and 0.1% was eventually diagnosed with CRC47. Screening detected cancers have been 
found to be of lower stage and the patients having better prognosis48-50. 
Staging 
 
Figure 1. Cuthbert Dukes. 
In 1936 the British pathologist Cuthbert Dukes wrote a paper on classification of rectal 
tumors51. It became the widely accepted classification system for CRC, grading the disease 
into Dukes A, B, C or D. It has later been replaced by the TNM system where T stands for 
tumor, N for nodal-involvement and M for (distant) metastases. 
  
 19 
 
 
T-stage 
TX – Primary tumor cannot be assessed 
T0 - No evidence of primary tumor 
Tcis - Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 - Tumor invades submucosa 
T2 - Tumor invades muscularis propria 
T3 - Tumor invades through the muscularis propria into the pericolorectal tissues 
T3a – Minimal invasion: <1mm beyond the borders of the muscularis propria 
T3b – Slight invasion: 1-5mm beyond the borders of the muscularis propria 
T3c – Moderate invasion: >5-15mm beyond the borders of the muscularis propria 
T3d – Extensive invasion: >15mm beyond the borders of the muscularis propria 
T4a - Tumor penetrates to the surface of the visceral peritoneum 
T4b - Tumor directly invades or is adherent to other organs or structures 
 
N-stage 
NX - Regional lymph nodes cannot be assessed 
N0 – No regional lymph node metastasis 
N1 - Metastasis in 1-3 regional lymph nodes 
N1a - Metastasis in 1 regional lymph node 
N1b - Metastasis in 2-3 regional lymph nodes 
N1c - Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or 
perirectal tissues without regional nodal metastasis 
N2 - Metastasis in 4 or more lymph nodes 
N2a - Metastasis in 4-6 regional lymph nodes 
N2b - Metastasis in 7 or more regional lymph nodes 
 
M-stage 
MX – Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
M1a - Metastasis confined to 1 organ or site 
M1b - Metastases in more than 1 organ/site or the peritoneum 
 
Table 1. TNM-classification52. 
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The T, N and M entities are combined to a TNM-stage, shown slightly abbreviated in the 
table below. 
Stage T N M 
0 Tis 0 0 
I 1-2 0 0 
II A 3 0 0 
II B-C 4a-b 0 0 
III 1-4 1-2 0 
IV 1-4 0-2 1 
Table 2. Abbreviated staging for colon cancer52. 
cTNM (‘c’ for clinical) is based on clinical findings and radiology. yTNM describes stage in 
patients whose first course of treatment consists of chemotherapy or radiation. pTNM (‘p’ for 
pathology) is based on clinical and radiological information, together with the information 
from the pathologists examination of the surgical specimen.  
Clinical presentation 
Often, early signs is non-specific but symptoms that should evoke suspicion of CRC are: 
anemia, blood in the stools or change of bowel habits53. General symptoms (including 
fatigue, weight loss and unknown fever) and anemia are more common in right-sided colon 
cancer whereas blood in stools and change in bowel habits are more commonly associated 
with left sided colon cancers54-56. Abdominal pain, change of bowel habits and acute 
symptoms are more common in higher disease stage, TNM-stage > II54. More than 80% of 
non-screening diagnosed patients had in a study anemia or visible blood in stools54. 
Clinical Workup 
The tumor is often diagnosed at a colonoscopy where a tissue sample is taken from the 
tumor. An alternative to colonoscopy is computed tomography of the colon (CT-colon) with 
the obvious disadvantage of inability to take tissue samples from a tumor. The patient is 
then often admitted for a computed tomography (CT) of the thorax and abdomen in the 
search for systemic disease or locally advanced cancer. The accuracy for pre-operative CT 
in staging of colon cancer was in a review 67%, 69% and 95% respectively for T, N and M 
stage57. Magnetic Resonance Imaging (MRI) can be used for pre-operative staging of colon 
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cancer with at least as good accuracy as CT but more resource consuming58. The 
biochemical tumor marker Carcinoembryonic antigen (CEA) has if used for diagnostic 
purposes both low sensitivity and specificity. CEA is merely used for baseline for future 
follow up and detection of relapse and as a marker for advanced disease. CEA is a useful 
marker for metastatic relapse and has also been found to be a pre-operative prognostic 
marker in colon cancer stage II59, 60. 
 
MDT-conference 
The principle to discuss individual patients at a Multi-Disciplinary Team (MDT)-
conference has been mostly developed regarding rectal cancer. More recently also colon 
cancer patients are more frequently discussed, not only post-operative, but also pre-
therapeutic. In clinical practice, at these often weekly meetings, individual patients are 
discussed by present surgeons, radiologists, oncologists, pathologists and contact-nurses. 
Typically the first MDT-meeting is held after the clinical workup is finished and the 
conference suggests a treatment for the patient. Regarding colon cancer, the most common 
decision at the pre-therapeutic MDT-conference is curatively intended surgery. Other 
possible decisions include neo-adjuvant chemotherapy, palliative chemotherapy or 
palliative surgery. Often the patient is discussed at a second MDT-meeting after surgery and 
the pathologist’s report of the specimen is highlighted and adjuvant treatment is perhaps 
recommended. 
There are no randomized studies on the effect on outcome for patients discussed (or not) at 
an MDT. Patients with rectal cancer are more frequently discussed at MDT-conferences 
than patients with colon cancer61. In the case of rectal cancer, being discussed at an MDT 
means increased probability for the patient to receive neo-adjuvant treatment62 and at 
surgery having a negative circumferential resection margin (CRM)63. Contemporary 
guidelines advices that “all patients with CRC should be treated within a framework of 
MDT-conferences”53. 
Surgical treatment 
Curative treatment for colon cancer includes resection of the tumor-bearing bowel segment. 
There are standard types of operations, depending on the location of the tumor. The types of 
standard resections are based on the knowledge of lymphatic drainage and lymph node 
anatomy. 
Right sided hemicolectomy is the standard type of operation for cancers in the caecum, the 
ascending colon, the hepatic flexure and in the proximal part of the transverse colon. In the 
case of a distal transverse cancer a so called “extended right sided hemicolectomy” can be 
done. The procedure includes division of the ICA, the RCA (if present) and the MCA, or at 
least its right branch. An anastomosis between the terminal ileum and the transverse colon 
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is made. 
Resection of the transverse colon is an oncologically limited type of operation for a 
malignancy in the transverse colon. Left sided hemicolectomy is the procedure for cancers 
in the left flexure or the descending colon. It includes division of the LCA and a transverso-
sigmoidal anastomosis. 
In the common case of cancer in the sigmoid colon, left-sided hemicolectomy or sigmoidal 
resection is done. The level of the vascular tie is often dependent of the extent of the bowel 
resection. If the cancer is situated in the distal sigmoid, or in the recto-sigmoidal junction, 
the upper part of the rectum is also removed, a so called PME, partial mesorectal excision. 
Colectomy, sub-total or total, is justified in the case of synchronous tumors in the colon or 
in patients with FAP or Lynch syndrome. Colectomy can also be advocated if the patient 
has had CRC earlier in life. If the rectum can be spared, the bowel-continuity can be 
accomplished with an ileo-rectal anastomosis (IRA). If not, a pelvic reservoir can be an 
alternative, especially in young patients53. 
 
Figure 2. CME-specimen from right sided hemicolectomy. Photo by Prof Werner 
Hohenberger. 
Complete Mesocolic Excision 
Complete Mesocolic Excision (CME) was first described by Professor Werner Hohenberger, 
University of Erlangen, Germany64. A similar description, but named ‘mobilization along 
anatomical planes’ comes from Professor Lesley Bokey, Sydney, Australia65. 
The main background reasoning with CME is that the lymphatic spread of a colon carcinoma 
follows the lymphatic vessels along the arteries and veins in the mesentery. These vessels are 
embedded in the mesentery, which is covered by a thin visceral fascia, like an envelope. If 
this visceral, peritoneal fascia is not breached, tumour spread will be, in theory, less likely. On 
the medial/front side of the mesocolon the peritoneal fascia is visible like a very thin, shiny 
surface. On the back/lateral side, this plane lies onto the retroperitoneal surface. The plane 
between the back side of the colon mesentery and the retroperitoneal area is sometimes called 
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the fascia of Toldt66. 
CME is applicable to left and right sided colectomies but here, and often elsewhere, mainly 
described and discussed for right sided hemicolectomies. The reason for this is probably that 
the anatomy is more challenging on the right side, both regarding the blood-vessels as well as 
other present organs such as the pancreas and the duodenum. 
One major part of a CME-operation is to separate the mesocolic/visceral fascia from the 
retroperitoneal surface in an embryologic plane. In the case of a right sided hemicolectomy, 
Hohenberger describes mobilization of the duodenum with the pancreatic head (Kocher’s 
maneuver) and the mesenteric root up to the origin of the superior mesenteric artery. Then, 
the uncinate process of the pancreas, with the mesopancreas and part of the duodenum is 
separated from the mesentery, ensuring access to the mesenteric vein. 
The other main component of a CME is the central vascular ligation (CVL). When the central 
vascular anatomy is exposed the operation includes a central tie and division of the supplying 
arteries, and veins, ensuring a large resected portion of the mesocolon, containing many 
lymph nodes. In the case of a cancer in the caecum or in the ascending colon, the ICA and the 
RCA (if existing) and the corresponding vein(s) are divided where they originate from the 
SMA and the SMV. The right branch of the MCA should be divided after its division. If the 
colon cancer is situated in the right flexure, in the transverse colon or in the left flexure, a 
more proximal division of the MCA is advocated. 
For tumors of the left colon, the splenic flexure is mobilized. The mesocolon of the 
descending colon and the sigmoid are dissected off the retroperitoneal plane leaving the 
prerenal fat, the ureter, the vesicular or ovarian vessels covered. The greater omentum is 
detached from the transverse colon for full exposure of the lesser sac and subsequent division 
of the transverse mesocolon at the lower edge of the pancreas. The LCA is divided64, 65. 
In Japanese literature colon resection for malignancies with dissection of lymph nodes near 
the SMA or SMV is called “D3-resection”67.  
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Figure 3. Cross sectional view of the right colon and its mesentery. Reprint with permission66. 
 
Figure 4. Schematic view of the Ileocolic Artery and corresponding lymph nodes. Reprint 
with permission67. 
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Vascular anatomy of the right colon with importance for Complete Mesocolic Excision 
Surgical challenges when handling a right sided cancer includes dissection close to the 
pancreas and the duodenum and a more complex vascular anatomy in the area of, or behind, 
the hepatic colonic flexure, with close relation to the pancreatic head and the duodenum. 
Several authors have performed cadaver dissections in order to study the vascular anatomy 
related to surgery of the right colon. In those studies, the ICA is always present, always arises 
from the SMA and can pass both anteriorly or posteriorly to the SMV2-4. Common is the 
description of a venous gastrocolic trunk anterior to the head of the pancreas, sometimes 
referred to as the Gastrocolic Trunk of Henle (GTH), that drains the confluence of the 
Superior Right Colic Vein (SRCV) and the right gastroepiploic vein (RGEV) and in turn 
draining into the SMV68, 69. The GHT is subject to extensive anatomical variations2. Well 
known for colorectal surgeons are the troublesome bleedings that can occur in the area of the 
right flexure/pancreatic head. This is often caused by excessive traction during surgery. These 
bleedings often comes from the SRCV which may be torn and retracted under the uncinate 
process of the pancreas. As mentioned above, the RCA is absent in many humans and 
therefore the SRCV has no corresponding artery and may therefore be difficult to anticipate 
during surgery68. The MCA inevitable arises from the SMA. The MCV drains into the SMV 
but in about 25% of individuals it does not convert into one stem before entering the SMV2. 
 
Figure 5. Photo of right colic venous anatomy. Reprint with permission68. 
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Figure 6. Venous variations. Reprint with permission68. 
Minimally invasive surgery 
Laparoscopic resections for colon cancer started to develop in the early 1990’s. Both short 
and long term outcomes have been studied in randomized controlled trials (RCT’s). The 
COLOR trial investigated 1248 patients that were randomized to open or laparoscopic 
resection for right- or left sided colon cancer. The laparoscopic operations took longer time 
but resulted in less blood loss. There were no differences in pTNM stage, lymph node yield 
or positive resection margins. The laparoscopically operated patients resumed digestive- 
and bowel functions quicker, were able to leave the hospital earlier and needed less 
analgesics postoperatively. Serious complications, both surgical and non-surgical did not 
differ between the groups70. In the long term follow up of the COLOR trial there were no 
differences in 3- or 5-year disease free survival (DFS) or overall survival (OS) and no 
difference in the frequency of hospitalization for bowel obstruction, depending on whether 
the patient had undergone laparoscopic or open surgery. The study could not, due to its non-
inferiority design, rule out that laparoscopic surgery for colon cancer is not inferior to open 
surgery71, 72. 
In the randomized CLASSIC trial patients operated laparoscopically did not have positive 
margins in a higher frequency and tumor- and nodal stage were similar73. 
The COST trial was a randomized multi-center study with 872 patients undergoing open or 
laparoscopic resections for colon cancer. There was no difference in cancer recurrence after 
4 years or in 5y OS74, 75. A meta-analysis of the COST, COLOR and CLASSIC studies 
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concluded that laparoscopic surgery for colon cancer is oncologically safe76. 
In a retrospective study from 2013, patients operated with a laparoscopic colorectal 
resection had a lower risk both for being admitted to hospital for bowel obstruction and for 
being operated for obstructing adhesions77. 
It is nowadays considered that laparoscopic resection for colon cancer has short term 
benefits and no obvious long term disadvantages, compared to open surgery. Laparoscopic 
colonic resections are more expensive than the open counterpart if looking at the costs for 
the operation and the healthcare system. Some of those costs are however regained when 
looking at society costs including for example sick-leave78. However there are patients and 
situations were laparoscopy according to many surgeons is not a method of choice, for 
example an abdomen with massive adhesions from previous surgery, locally advanced T4 
tumors and an emergency situation with obstructed or perforated bowel. Many surgeons 
with experience from laparoscopic colonic resections are also of the opinion that tumors 
located in the flexures or in the transverse colon are not perfectly suitable for laparoscopic 
resection although shown feasible79, 80. 
In Sweden, the proportion of resections for colon cancer performed with laparoscopy has, 
compared to other European and Nordic countries, been low but has increased after 201081 
although many patients probably eligible for laparoscopic surgery are still operated with 
open surgery82. 
Robotic surgery 
Robot assisted laparoscopic surgery was introduced in the previous decade. When referred 
to a “robotic” operation one usually means a laparoscopic operation where two or more 
ports/instruments are operated by the robotic system but controlled by a human surgeon at 
the console in the operating room a few meters from the patient. Typically, a second 
surgeon/assistant is operating conventional laparoscopic instruments bedside. Often 
mentioned benefits with robot assisted laparoscopic surgery are superior high-definition 
view, improved ergonomics and ability to work with high precision in confined spaces. 
An early established area of use for the robotic system was prostatectomy for prostate 
cancer. Robot assisted laparoscopic radical prostatectomy seems to be oncologically safe83. 
In a prospective non-randomized comparison between open retro pubic radical 
prostatectomy and robot assisted laparoscopic prostatectomy (the LAPPRO-study) the 
authors concludes that there was no difference in urinary leakage and a modest benefit for 
robot assisted laparoscopy regarding erectile dysfunction84. Robot assisted laparoscopic 
radical prostatectomy is more expensive than open retro pubic radical prostatectomy85, 86. 
Robotic assisted laparoscopic colorectal resection surgery has also been established. In the 
case of rectal cancer there are several studies comparing robotic assisted laparoscopic 
surgery with conventional laparoscopic surgery. Robot assisted laparoscopic surgery is 
according to the majority of these studies associated with longer operating time87-89. There 
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are no differences in short term oncological parameters such as lymph node yield or 
positive margins88-91. The robotic operations seem to be converted to open surgery to a 
lesser extent and there is less short term serious complications associated with robot assisted 
laparoscopic operations than conventional laparoscopic surgery87, 92. There are no studies 
comparing robotic surgery for rectal cancer to open surgery but laparoscopic surgery for 
rectal cancer is oncologically equivalent to open surgery93. 
Robot assisted laparoscopic right hemicolectomy for cancer has also been demonstrated 
feasible94, yielding less blood loss and shorter time to first post-operative flatus but longer 
operation time and is more expensive95. 
Adverse events 
Resection surgery for colon cancer is vitiated with complications. Complications of any 
kind have been reported in more than one in four patients undergoing colorectal resection 
surgery96. Major postoperative complications include wound infection, anastomotic leakage 
(AL), ileus and bleeding97. Pre-operative, patient related risk-factors for encountering 
complications in general, non-thoracic surgery includes American Society of 
Anesthesiologists (ASA) grading >2, emergency surgery and congestive heart failure98. In 
laparoscopic colorectal surgery male gender, ASA>2 and age >=75 have been found to be 
risk factors for complications99. 
In segmental colonic resection with formation of an anastomosis, AL is a specific and 
feared complication. It is associated with morbidity, mortality, prolonged hospital stay and 
suffering. In order to heal properly, the anastomosis must be tension-free and have an 
adequate blood supply100. In an AL, the integrity of the anastomosis is for some reason 
compromised and intraluminal bowel contents and/or fluid is displaced out into the 
peritoneal cavity, causing inflammation, sepsis and later abscesses. The condition is often 
revealed within a week from the index operation but sometimes later101. Typically, the 
patient’s condition is worsened with ileus, abdominal pain, fever, rising inflammatory 
parameters and sometimes hemodynamic instability. Abdominal CT scan has a high 
sensitivity for detecting AL101, but sometimes the diagnosis is made upon re-laparotomy. 
There is no universal definition of AL102. The frequency of AL after colonic resections (not 
involving anastomoses to the rectum) has been found to be 1-4% and short term mortality 
after AL 6-16%101, 103, 104. Male gender is a risk factor for AL103-105, as is smoking, alcohol 
consumption and ASA>2100. Regarding obesity and steroid use and risk for AL, data points 
in different directions100. In a Cochrane review from 2011, based on six studies, of which at 
least four contained cancer resections, there was a lower frequency of AL after stapled 
ileocolic anastomoses106. In contrary, a large Swedish population based study, showed that 
hand-sewn ileocolic anastomoses had a lower leakage rate than stapled107. A recent study 
found an increased risk for AL with stapled anastomosis in right sided hemicolectomy108. 
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Even adjusted for disease stage, age and 30-day mortality AL is negatively associated with 
overall survival and cancer specific survival103, 104, 109. 
Centralization of surgery 
Treatment for colon cancer is nowadays a complex procedure with many components. 
There has been a debate in Sweden and in other countries regarding centralization, in other 
words that treatment for a specific condition should be given in fewer hospitals. The 
foremost argument for centralization is higher caseloads for individual surgeons and teams, 
proposedly leading to better short- and long term results. Other argued pros with 
centralization includes ability to introduce new technology and methods, improved 
conditions for teaching, research and learning, better conditions for MDT-conferences and 
better abilities to treat patients with advanced co-morbidities. 
Arguments against centralization of colon cancer treatment comprises lack of evidence that 
high volume yields better results, consequences for other specialties and patients, more 
difficult to recruit and keep, surgeons and also the argument that both information 
technology and transport logistics make smaller hospitals coming closer to larger centers. 
 
In a Danish study of AL after resections for colon cancer, patients were included over a 
period of 7.5 years. During the study, the number of hospitals performing resections for 
colon cancer decreased from 48 to 28 without a decrease in the frequency of AL105. A 
Swedish study showed improved 5-year overall survival after surgery for rectal cancer in a 
region when surgery for those patients was centralized from four to one hospital and a 
dedicated colorectal unit was formed110. The same group also reported improved results 
after surgery for sigmoid tumors after the above described centralization111. Another 
Swedish study showed that patients operated for rectal cancer where a surgeon operating at 
least 12 such operations a year participated had a better outcome112. A Cochrane review 
from 2011 concludes that high-volume hospitals and, especially, high-volume- and 
specialized colorectal surgeons is associated with better long term OS113. In the Stockholm 
area, the number of hospitals surgically treating CRC, have the last decade decreased from 
eight to five, while the population at the same time is increasing. 
Emergency presentation 
The definitions of “emergency” presentation and acute operation are heterogeneous. The 
proportion of patients that have their colon tumor resected emergently is high, often 
reported to be over 20%. Emergency resection of a colon cancer is associated with poor 
outcome, both in the short and in the longer perspective. In the long term, emergency 
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presentation or operation carries a worse prognosis, even after exclusion for early post-
operative deaths and adjustment for sex, age and stage114-117. 
Pathology 
More than 90% of colon tumors are adenocarcinomas. Mucinous cancer is a subtype of 
adenocarcinoma where more than 50% of the tumor consists of mucin producing epithelium 
and “pools” of mucin. It accounts for about 10-15% of all CRC’s. Signet ring cells 
carcinoma, named by its appearance in microscopic view, is rare, representing maybe 1% of 
all CRC’s and has worse prognosis. Mucinous cancers presents in later stages but stage-
adjusted they don’t have worse prognosis than ordinary adenocarcinomas. Some but not all 
studies show that patients with mucinous cancers are younger118, 119. 
When the bowel specimen, including the tumor, has been resected it is sent to the pathology 
department. It can be sent fresh or fixed in formalin. Macroscopic evaluation and 
photographing is recommended. Tumor site and planes of surgery is evaluated and the 
surgical planes are dyed with ink. The mesocolon is dissected for lymph nodes. To facilitate 
the finding of lymph nodes, fat clearing agents can be used120. Samples for microscopic 
evaluation is taken and evaluated for T-stage, clear resection margins, tumor deposits, 
extramural lympho-vascular invasion (LVI) and peri-neural invasion53, 121. 
CRM has been defined for rectal cancer specimens. It is defined as the shortest distance 
from the tumor border to the resection margin. 1 mm or less is defined as a positive CRM. 
More than 1 mm is defined as a negative CRM. Positive CRM is associated with inferior 
outcome in rectal cancer122, 123. The term CRM is much less used in colon cancer although 
microscopically radical surgery is as important for tumor clearance and survival124, 125. 
Lymph node yield 
One of the crucial factors for prognosis and possible adjuvant treatment is the examination 
of lymph nodes from the colonic mesentery. Already in 1909 Jamieson and Dobson 
described the necessity of removing relevant lymph nodes at surgery for colon cancer126. If 
the examined lymph nodes contain tumor cells the patient is graded as at least N1 and 
thereby pTNM stage III. This has implications both regarding prognosis as well the decision 
to offer the patient adjuvant chemotherapy. Studies regarding the relationship between the 
number of analyzed lymph nodes and the probability of a false negative classification of 
node positive disease show that the adequate number is depending on T-stage. According to 
Wu et al, the statistical number of required analyzed nodes to correctly diagnose the N-stage 
with 80% confidence is for T1-tumors three nodes, for T2-tumors eight nodes and for T3-
tumors 24 nodes127. In table 3 the probability for the patient not having lymph node 
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metastases is shown, in relation to T-stage and the number of examined, healthy lymph 
nodes128. 
 
Nodes 
/stage 
1 5 8 10 12 15 18 20 25 
T1 91.5 96.3 97.5 98.0 98.3 98.7 98.9 99.0 99.2 
T2 84.5 92.9 95.2 96.1 96.7 97.4 97.8 98.1 98.5 
T3 60.8 78.9 84.9 87.4 89.3 91.3 92.8 93.5 94.9 
T4 47.9 68.9 76.9 80.5 83.2 86.2 88.4 89.5 91.7 
Table 3. Probability of true N0-stage related to number of analysed non-metastatic lymph 
nodes. Reprint with permission128. 
pT1 and pT2 tumours carries a relatively low risk of lymph node metastases128, 129. There 
are Japanese studies on lymph node metastases patterns, mentioning findings in central, D3 
lymph nodes in less than 6% of specimens130. 
The minimum number of lymph nodes that the pathologist need to examine in order to 
correctly classify the patient as N0 or N+, has been debated. In Sweden, as well as in the 
United States and in Germany, there are guidelines suggesting a minimum of 12 examined 
lymph nodes as a marker for quality in colon cancer surgery53, 131, 132. There are more lymph 
nodes retrieved from younger patients and more nodes from right sided cancers compared to 
left side131, 133. In a study of more than 7000 surgically resected CRC patients Morris et al 
describes many factors influencing the numerical lymph node yield such as tumor 
characteristics, patient age, calendar year and degree of specialization of surgeons and 
pathologists134. Both in node-negative and node-positive colon cancer, the number of 
analyzed lymph nodes removed at surgery are influencing survival. Low numbers are 
associated with a worse prognosis135-138. The number of metastatic lymph nodes divided by 
the number of analyzed nodes has been named Metastatic Index (MI), Index of Metastases 
or Lymph Node Ratio. Lower numbers are associated with a better prognosis139, 140  
Stage migration 
When more lymph nodes are analyzed by the pathologist, the probability to find a node 
containing cancer cells increases. An effect of stage migration is that the characteristics of 
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patient groups are altered. If the hypothetical last lymph node examined in a specimen 
contains cancer cells, that patient is moved from stage I-II to stage III. In theory, a patient 
with high risk for relapse within stage I-II is instead placed in stage III and there maybe 
representing a relatively early case. This may actually improve survival both groups (I+II 
and III) and is sometimes described as the Will-Rogers phenomenon131, 141. 
Adjuvant treatment 
Stage III colon cancer patients benefit from adjuvant chemotherapy with improved DFS and 
OS142. In stage II adjuvant treatment is debatable. Many stage II patients have a prognosis 
similar to stage I. However there are some prognostic factors entailing worse prognosis in 
stage II. These include T4, bowel perforation or occlusion, high grade tumor (low 
differentiated) or LVI. Patients with these attributes probably benefits from adjuvant 
chemotherapy143. In colon cancer, LVI is associated with local recurrence but not impaired 
OS144. 
Prognosis 
Patients with colon cancer constitutes a heterogeneous group where prognosis varies, 
depending on many factors. Survival can be measured in different ways. Often DFS or OS 
have been used as endpoints. Relapse free survival (RFS) and time to event (TTE) are 
examples of surrogate markers for survival145. In a Swedish material published in 2013, there 
was an actuarial, crude, three year OS of 62.7% and for patients undergoing elective tumor 
resection three year relative survival was 83,7%146. In the long-term follow up of the COLOR 
trial (stage I-III, elective resection) the three year DFS was approximatively 75% and five 
year OS was approximatively 74%71. 
Patients in stage I have a good prognosis with long term survival exceeding 90%71, 147. 
Non-high-risk stage II patients have a prognosis almost as advantageous as those of stage I143. 
In an adjuvant treatment study, five year DFS was for high risk stage II patients 79,9%-83,7% 
and in stage III 58,9%-66,4%, varying with chemotherapy regime142. 
Stage IV, although a heterogeneous condition, entails a bad prognosis. A French study, albeit 
20 years old, on patients having liver resection for metastases, three year actuarial OS was 
44% and at five years 28%148. 
Stage is a strong marker for DFS as well as OS. There is a strong correlation between three 
years DFS and five years OS71, 149. As in the study of many other diseases, age is a very 
prominent factor for both OS and DFS and in colon cancer age is also associated with worse 
cancer specific survival150, 151. 
In summary, colon cancer stage I-II has good prognosis, stage III has a mediocre prognosis 
and stage IV has as a group, in spite of vast achievements the last decades, bad prognosis.  
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Swedish ColoRectal Cancer Registry (SCRCR) 
The Swedish ColoRectal Cancer Registry (SCRCR) is a national registry with prospectively 
registered data on colon cancer and rectal cancer. The SCRCR has data on rectal cancer 
since 1995 and colon cancer since 2007. In the Stockholm region there is a regional registry 
with data on colon cancer since 1997. The SCRCR contains numerous variables including 
treating hospital, age, sex, dates for diagnosis and operation, tumor location, pre-treatment 
staging, neo-adjuvant treatment, type of surgery, length of hospital stay, short term 
morbidity, post-operative staging, dates for MDT-conferences, adjuvant treatment, relapse 
and recurrence. Information regarding death is available through linkage to the Cause of 
Death registry. Information on other malignancies is available through linkage to The 
Swedish Cancer Registry. Linkage to other registries is enabled by the Swedish personal 
number, unique for every individual. The SCRCR has been validated and has a patient 
coverage of >99% and a coverage in terms of correctly registered variables of >90% and a 
high validity152, 153. Surgical complications are under-reported although re-operations seems 
adequately reported154. 
Follow up 
The national Swedish guidelines recommend a follow-up of five years after treatment for 
colon cancer stratified on pathological stage53. All patients have their CEA-level measured 
preoperatively and 1, 3 and 5 years postoperatively. CT scan of the thorax and the abdomen 
should according to the guidelines be performed after one and three years postoperatively at 
a minimum. After complete, preoperative colonoscopy an endoscopic follow-up is 
recommended three to five years postoperatively. Postoperative chemotherapy is 
recommended for patients with pathological stage III disease or stage II disease with risk 
factors. Time to local recurrence, distant metastases or death is registered prospectively in 
SCRCR. Registration of local recurrence is underreported in SCRCR in case of 
synchronous finding of distant metastasis during follow-up. Relapse includes therefore the 
events of local recurrence and/ or systemic disease. The date of death is registered in 
SCRCR based on the official Civil Registry. 
Stockholm Colon Cancer Project 
In 2004 an educational project, similar to the TME-project (described in ‘discussion’), was 
launched. It was called the Stockholm Colon Cancer Project (SCCP) and the aim was to 
introduce the MDT-concept and CME surgery in colon cancer. The target group was 
surgeons, radiologists, oncologists and pathologists treating patients with CRC in the 
Stockholm area. Recurrent meetings were held annually including lectures, discussions and 
live demonstration-surgery with domestic and international surgeons demonstrating CME-
surgery. Also specimens from colon cancer were demonstrated and discussed. At these 
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meetings it was also emphasized that emergency resection of colon cancer entails poorer 
prognosis and should be avoided if possible. 
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AIMS OF THE THESIS    
Overall aim 
To evaluate the introduction of CME in clinical practice and the impact on short- and long 
term outcome for patients with for colon cancer. 
Specific aims 
 
Paper I 
To assess the number of lymph nodes in the specimen and MI after surgery for right sided 
colon cancer in the Stockholm area between 1996 and 2009. 
Paper II 
To assess the impact of the SCCP on survival for patients diagnosed with right sided colon 
cancer in the county of Stockholm.  
Paper III 
To assess the association between CME and serious short term adverse events. 
Paper IV 
To evaluate the effect of CME on oncological outcomes after surgery for right sided colon 
cancer.  
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PATIENTS AND METHODS   
Paper I 
All patients surgically treated for adenocarcinoma in the caecum, the ascending colon or the 
hepatic flexure, in the Stockholm area, between January 1st 1996 and December 31st 2009 
were included in the study. Data on patient characteristics, tumor location, stage, type of 
surgery, specimen data (including lymph node status) were collected from the SCRCR. The 
study period was divided into three groups, based on the calendar year in which they were 
operated, Period 1 (1996-1999), Period 2 (2000-2004) and Period 3 (2005-2009). Parameters 
studied were age, sex, tumor location, tumor stage, emergency or elective operation, number 
of lymph nodes analyzed by the pathologist, number of metastatic lymph nodes. Among 
lymph node positive patients, mi was calculated by dividing the number of metastatic lymph 
nodes by the number of examined lymph nodes. 
Differences in the distribution of qualitative variables with respect to time period and other 
categorical variables were assessed using the chi-square test. The number of lymph nodes and 
mi, with respect to dichotomous variables were compared using Wilcoxon two-sample test 
and, for variables with more than two categories, using the Kruskal-Wallis test. 
Paper II 
The Stockholm colon cancer project (SCCP) has been described in the background to this 
thesis. All patients diagnosed with adenocarcinoma in the caecum, the ascending colon or the 
hepatic flexure during two time periods before and after the start of the SCCP (January 1st 
2001 to December 31st 2003 (Group 1) and January 1st 2006 to December 31st 2008(Group 2)) 
were included in the study. Data were obtained from the SCRCR regarding age, sex, tumor 
stage (TNM), whether the tumor had been resected or not, type of surgery, emergent or 
planned surgery, neoadjuvant and adjuvant treatment, failure events (local recurrence, distant 
metastases and death) and survival times. Survival between the two groups and between 
different pTNM-stages were compared. 
Proportions were compared using the Chi-square test. Differences in patient age between the 
groups were compared with the Students t-test. OS was calculated from the date of diagnosis. 
DFS was calculated from the date of tumor resection and patients were considered to be at 
risk until the diagnosis of local recurrence, metastases or death from any cause. Survival was 
measured using the Kaplan-Meier method and differences between the two groups were 
assessed with the Log-Rank test. Death specific hazards modelling was performed using 
Cox’s proportional hazards regression including potential confounding factors. Hazard ratios 
(HR) were calculated along with 95% confidence intervals (CI) and were analyzed 
statistically by means of likelihood ratio tests. 
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Paper III 
All patients operated for adenocarcinoma in the caecum, ascending colon or the hepatic 
flexure, between January 1st 2004 and December 31st 2012 were the study base for this nested 
case-control study. Patients that died within 90 days of tumor resection or had an emergency 
re-operation within 30 days or within hospital stay were identified as cases. Two controls per 
case were randomly selected from the study base and matched for sex, age-interval, TNM-
stage and emergency vs. elective surgery. 
Exposure was defined as CME. Exposure status was determined from original surgical 
reports, blinded for surgeon’s name(s), date of surgery, patient age, sex and hospital and 
whether the patient was a case or a control. Two colorectal surgeons each read all the surgical 
reports. The reports were classified as “CME”, “no CME” or “CME unclear” according to 
pre-defined criteria. 
1 Dissection of the mesocolon from the duodenum and the head of pancreas 
2 Visualization of the superior mesenteric vein 
3 Ligation of the ileocolic or right colic vessels at the level of the superior mesenteric 
vein 
4 Ligation of the right branch of the middle colic vessels at its origin or central 
ligation of the middle colic vessels 
5 Integrity of the mesocolon and the resected bowel segment 
Table 4. Criteria for classifying a surgical report as CME. 
 
Reports classed as “CME unclear” or with discordance between the reviewers were re-
assessed by both the initial reviewers and a third colorectal surgeon, all three blinded to the 
initial assessment. 
Comparison between the groups (cases and controls) was made with Wilcoxon Rank-sum test 
(continuous variables) and Fisher’s exact test (dichotomous variables). Crude odds ratios 
(OR) with exact CI were calculated for the combined outcome (reoperation or short-term 
mortality) and for both outcomes separately. Conditional logistic regression was used to 
account for individually matched sets of cases with two controls. The confounding effect of 
matching variables and ASA was assessed by comparison between basic and adjusted 
conditional logistic regression models. 
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Paper IV 
All patients, operated for adenocarcinoma in the caecum, the ascending colon or the hepatic 
flexure, in the Stockholm County from January 1st 2008 until December 31st 2012 were 
identified in the SCRCR. Patients registered as emergent colonic resections or with 
synchronous systemic were excluded. Local recurrence, metachronous systemic disease and 
survival were compared between patients treated with or without CME surgery. The exposure 
to CME surgery was assessed from original surgical reports, anonymized regarding 
surgeon(s) names, date of surgery and hospital. Two colorectal surgeons classified the reports 
independently according to five predefined criteria as shown in table 4. 
The surgical reports were classified into the following three categories, “CME”, “CME 
uncertain” and “no CME”. Reports with discordance regarding CME status between the two 
reviewers were assessed by a third colorectal surgeon, blinded to the result of the initial 
assessment, to reach a majority decision on the classification of CME surgery. If all three 
reviewers took a different standpoint the report was classed as “CME uncertain”. 
Statistics 
For comparisons of the three groups of CME surgery, Kruskal-Wallis tests (continuous 
variables) and Fisher’s exact tests (categorical variables) were used. Time to relapse or 
death was analysed with the Kaplan-Meier method and groups compared with log-rank 
tests. For the analysis of relapse, patients were censored at the time of death or last follow-
up. Local or systemic recurrence and death of any cause were the events in the analysis of 
relapse-free survival (RFS). Death of any cause was the event in OS. Patients were censored 
at the time of last follow-up in survival analysis. The assumption of proportional hazards 
was assessed for RFS and OS with “log-log” plots and on the basis of Schoenfeld residuals. 
Cox regression was then used to assess the prognostic and confounding effect of covariates 
in uni- and multivariable models. Age (dichotomized at median age of 75 years), gender, 
ASA-class, pTNM-stage and adjuvant treatment were included in multivariable models. 
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RESULTS      
Paper I 
3536 patients were operated in Stockholm for right sided colon cancer during the study 
period. There were more women than men operated in the study, 57% compared to 43% but 
no difference within the three time periods. There were fewer patients having their colon 
cancer resected in an emergency operation during the last period of the study, 14.9% 
compared to 17.4% and 20.7% in period 1 and 2 respectively (p<0.001). The number of 
analyzed lymph nodes rose from seven (mean) in period 1 to 11 in period 2 and 18 in period 3 
(p<0.001). The proportion of patients having less than 12 lymph nodes analyzed in the 
specimen was 77.1% in period 1, 55.8% in period 2 and 18.3% in period 3 (p<0.001). The 
mean number of metastatic lymph nodes increased from two in period 1 to four in period 3 
(p<0.001). MI was 0.40 in period 1 and 2, compared to 0.25 in period 3 (p<0.001). MI 
decreased with an increasing number of analyzed lymph nodes. Patients were more likely to 
be staged as pTNM stage III if more than five lymph nodes were detected in the specimen 
(p<0.001). Men were more likely to have five or less lymph nodes analyzed and women were 
more likely to have >11 lymph nodes analyzed (p=0.008). 
Paper II 
During the two time periods, 1716 patients were diagnosed with right sided colon cancer, 819 
patients in Group 1 and 897 patients in Group 2. There were more women than men in both 
groups. 
The proportion of patients having a tumor resection was larger in Group 1, 96.6% compared 
to 91.2% in Group 2 (p<0.001). There were a larger proportion of patients having emergency 
tumour resection in Group 1. Group 2 had a larger proportion of patients with stage I disease. 
There was a significantly higher proportion of R0 resection in Group 2.  
There were a crude OS at three years after diagnosis of 61.3% in Group 2 vs 56.0% in Group 
1 (p=0.025). The crude three year disease free survival among patients in TNM stage I-III 
who had their tumor resected was also significantly higher in Group 2, 71.5% compared to 
64.6% in Group 1 (p=0.006). 
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Figure 7. DFS in patients with pTNM stage I-II and III within Group 1 and 2. 
 
In a multivariable analysis patients in Group 2 had a HR for DFS of 0.79 (95% CI: 
0.64.0.97)(p=0.022) compared to patients in Group 1. Other factors entailed with a HR for a 
worse DFS was emergency surgery and age > 69 years. 
Paper III 
During the study period 2464 patients were operated for right-sided colon cancer in the 
Stockholm County. After exclusion of patients with distant metastases, unknown disease 
stage or unknown date of surgery 2070 patients remained. Of these, 240 patients died within 
90 days after surgery and/or were re-operated and were therefore included as cases. 480 
individually matched controls were randomly selected from the SCRCR. The surgical reports 
could not be retrieved in four cases and in seven controls. The matching process resulted in a 
similar distribution of age, sex, tumour stage and proportions of emergent versus elective 
procedures among cases and controls. ASA score was available in 69% of the patients. ASA 
3-4 was significantly higher among cases than controls; 62.1% versus 42.4% (p<0.01). 
After reassessment of the group “CME unclear” and those where the two reviewers initially 
disagreed, a binary CME status was agreed for all 236 cases and 473 controls. The proportion 
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of CME-surgery was 14.8% (35 of 236) in cases and 19.5% (92 of 473) in controls. 
The crude OR for short-term mortality or re-operation following CME-surgery was 0.72 
(95%CI 0.47-1.10; p=0.15) compared to no CME-surgery. In the unadjusted conditional 
logistic regression model, OR for postoperative death or re-operation was 0.75 (95% CI: 0.50-
1.13; p=0.17) for CME surgery compared to no CME surgery. The adjusted models showed 
no evidence for relevant confounding by matching factors or ASA. When the study period 
was divided into three time-periods, OR for postoperative death or re-operation was 0.51 
(95% CI: 0.26-1.01; p=0.05) for CME surgery compared to no CME surgery in the last third 
of the study. In hospitals operating more than 100 patients in the study, OR for postoperative 
death or re-operation was 0.61 (95% CI: 0.35-1.06; p=0.08) for CME surgery compared to no 
CME surgery. 
Paper IV 
During the study period 1542 patients were operated for right-sided colon cancer in nine 
different hospitals in the Stockholm County. After exclusion of patients with systemic 
disease, emergency surgery or missing data regarding hospital, surgical report or systemic 
disease, 1171 patients could be analysed. 
In 727 patients (62.1%), both colorectal surgeons agreed in the classification of CME status. 
The third colorectal surgeon assessed the remaining 444 surgical reports. The final 
classification of surgical reports was “CME” in 357 (30.5%), “CME uncertain” in 273 
(23.3%) and “no CME” in 541 (46.2%). Median age was lower for patients with surgical 
reports classified as “CME” compared to the groups classified as “CME uncertain” and “no 
CME” (72 vs 75 vs 77 years respectively, p<0.001) and had a lower ASA-score (p<0.001). 
The proportion of laparoscopic resections were lower in the “CME” group (5.4% vs 11.7% 
and 17.2% respectively, p<0.001). The three categories of CME surgery did not differ 
statistically regarding proportion of R0-resections (95.8 to 97.8%), 30-day mortality (1.4 to 
2.8%) or risk for reoperation (8.1 to 10.0%). The distribution of pTNM-stage was different 
(p<0.001) with the highest proportion of stage III disease in the “CME” group (38.7%) and 
the highest proportion of stage I disease in the “no CME” group (24.8 %). The median 
number of analyzed lymph nodes was highest among patients with “CME” (n=20) and lowest 
in the “no CME” group (n=16) (p<0.001). Patients in the “CME” group were followed for 66 
months (median)(range 0-107 months), the patients in the “CME uncertain” group for 65 
months (0-106) and the patients in the “no CME” group for 61 months (0-107). Five year 
RFS was 73.6% in the “CME” group vs 72.4% in the “CME uncertain” group vs 63.5% in the 
“no CME” group. Five year OS was 76.1% in the “CME” group vs 76.1% in the “CME 
uncertain” group vs 65.8% in the “no CME”. 
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Figure 8. Five year RFS after surgery for right sided colon cancer (p=0.062 (Log-Rank 
test)) 
The univariable Cox regression analysis showed improved RFS for patients with surgical 
reports classified as “CME” HR=0.64 (CI: 0.51-0.81, p<0.001) and “CME uncertain” 
HR=0.76 (CI: 0.60-0.96, p=0.023). Age, ASA and pathological stage changed the 
unadjusted HRs of CME status by more than 10% and were considered as confounders. The 
final model, adjusted for age, gender, ASA, laparoscopic technique, adjuvant chemotherapy 
and pTNM-stage showed a significantly improved RFS for “CME” HR=0.74 (95% CI: 
0.58-0.94, p=0.014) and a trend to improved RFS for “CME uncertain”, HR=0.80 (95% CI: 
0.63-1.03, p=0.078). 
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DISCUSSION     
In the 1980’s surgical treatment of rectal cancer went through a paradigm shift with the 
introduction of the TME concept155, 156. This concept included dissection and mobilization of 
the rectum along an embryonal plane, behind the mesorectum, respecting the mesorectal 
fascia. In studies this was proven leading to improved results in terms of local recurrence and 
OS157, 158. In Stockholm the TME-concept was introduced in an educational project in 
1994158. This project compromised workshops, discussions, lectures and video-based live 
surgery sessions. A majority of surgeons in Stockholm at that time treating patients with 
rectal cancer attended and many had the opportunity to assist in the operating theatre. In a five 
year follow up of patients operated during 1995 and 1996 the results were gratifying. 
Compared to historical controls, patients operated within the “TME-project” had a rate of 
local recurrence of 8%, compared to earlier 19-22%. 5-year cancer specific survival was 77% 
compared to 66%159. 
Historically, prognosis for rectal cancer has been inferior to the prognosis for colon cancer. 
Coincident in time with the introduction of TME, the prognosis for rectal cancer improved 
faster than the one for colon cancer and this was ascribed the introduction of TME-surgery 
and pre-operative radiotherapy160.  
 
Figure 9. Observed survival-rates in colon- and rectal cancer in Sweden. Reprint with 
permission160. 
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The concept of TME is largely based on the concept of embryonal layers. This concept has 
also been translated into the practice of colon cancer management. 
In Australia, Bokey et al describes the introduction of a new technique in the early 1980’s 
with “precise dissection along anatomic planes, facilitating an operation that will not 
compromise or breach the fascial envelope of the colon and it’s mesentery”65. Further, Bokey 
describes the aim of the surgery as: “...to perform a bloodless extra fascial dissection with 
minimal handling of the tumour and to remove the entire specimen as an ‘intact package’ 
without disrupting the embryological tissue planes, thus minimizing the potential for surgical 
transection of the tumour. These techniques also entailed ligation of the lymphovascular 
bundle at the origins of the relevant principal named vessels.”161 It is also since 
approximatively the same time frame that Hohenberger describes the evolvement of CME in 
Erlangen64. 
It has been questioned if CME is a new surgical technique or merely an old technique that has 
gained attention and been refined lately162. More than a century ago Jamieson et al wrote: 
“The ideal operation consists in removing a considerable length of gut on each side of the 
growth, the primary glands, together with the vessels running to the from the gut, and the 
tissues in which these vessels lie, i.e. the so-called lymphatic area.” He also wrote, regarding 
surgery for neoplasms in the right colon: “The artery and vein are ligated and divided close to 
the superior mesenteric artery”126. 
Introduction of a more or less new surgical technique raises justifiable questions. When TME 
was introduced criticism was endured in the beginning and Professor RJ Heald was 
disbelieved when presenting new figures with low frequencies of local recurrence. There is a 
risk that a new surgical technique is introduced first and evaluated later. A new technique may 
look good, feel good and have eloquent advocates. For example, laparoscopic 
cholecystectomy was introduced in the second half of the1980’s and became the method of 
choice without scientific evidence. The introduction of laparoscopic cholecystectomy 
increased the frequency of bile duct injuries163, 164. The comparison between open and 
laparoscopic cholecystectomy came later with small randomized studies of varying external 
validity during the first half of the 1990’s165. Laparoscopic appendectomy has also been 
introduced widely as a standard treatment for acute appendicitis. There are benefits in certain 
patient groups but in general the advantages over open appendectomy are small and the 
operation takes longer time and is more expensive166. In Sweden, robot assisted laparoscopic 
surgery has been introduced for a number of surgical procedures even though the scientific 
evidence for clear advantages are absent167. In the last decade CME has been introduced and 
implemented as a more or less new surgical technique. The need to evaluate what this has 
meant for surgical treatment of colon cancer was the background for this work. 
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Randomized trials? 
There are, yet, no RCT’s between CME and standard resection for colon cancer. 
It might be possible to randomize between D2 and D3 surgery or, in other words, between 
CVL and non-CVL. However there would be cases where the surgeon intra-operatively 
suspects for example D3 lymph node metastases and if that particular patient is randomized to 
D2 surgery the patient has to be excluded from the study. This would of course introduce 
bias. There are other hypothetical peri-operative events, findings and decisions that would 
exclude patients and causing bias. There might also be increasingly difficult to inform and 
discuss the possible differences with the patients since there are several papers included in, 
and discussed within this thesis showing a long term advantage with CME-surgery. In order 
to design and conduct a RCT between an old a new (surgical) treatment, there must be an 
unawareness of which treatment is the best. There must not be strong opinions or beliefs in 
the new treatment being better (or worse). There must be ‘equipoise’, i.e. there must be 
substantial uncertainty about the relative value of one treatment versus another. This can be 
applied to the individual surgeon or to the collective of informed surgeons168-172.  
How do we know if CME-surgery has been performed? 
In the absence of RCT’s, there have been different efforts to evaluate CME compared to 
conventional colonic resection surgery for cancer. 
Firstly, there are published single-center case series. In these, there are sometimes few, 
dedicated surgeons operating the patients. There are authors presenting very impressive 
results64, 173 although the grade of scientific evidence in case-series types of studies is 
considered low174. 
Secondly, the comparison of different time-periods has been made, with the assumption that 
CME has been introduced in between the periods, among others in our paper II. Comparison 
with an historical control-group is a known weakness of study design. It is difficult to know to 
what degree the assumption that CME is not done in the early period and that it is done in the 
late period is correct. There might also be other parameters that have changed between the 
time periods and that one fails to adjust for in the statistical analysis, for example changing 
chemotherapy guidelines and centralization of treatment. 
Another potential method is to compare hospitals were CME is implemented with others 
where CME is proposedly not practiced. This approach was used by Bertelsen, Storli and 
West175-177. It has maybe an advantage over comparison of time periods, in the sense that 
there might have been instructions and guidelines promoting the use of CME at the “CME 
hospital(s)”. Otherwise this method may suffer from the same type of bias as the comparison 
of time periods. 
Moreover, there are interesting attempts on evaluating whether CME has been done by 
radiological examinations post-operatively. In a Danish study the patients were examined 
with CT Angiography two days post-operatively and the stump of the ICA was measured. 
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Munkedal et al found that the mean length of the remaining ICA stump after right sided 
hemicolectomy was 31mm and a trend towards a negative correlation between the length of 
the arterial stump and the number of lymph nodes in the specimen (p=0.06)178. In a 
Norwegian study, patients that were x-rayed on suspicion of AL also had the arterial stump 
measured. The average radiological, post-operative, length of the ICA stump was 24mm179. In 
a study from Leeds, Kaye et al found that the ICA-stump after right-sided hemicolectomy was 
in average 28.1mm180. The disadvantages with these studies are size, the Danish and the 
Norwegian study contains 52 and 18 patients respectively. The consistent conclusion of these 
post-operative radiological evaluations is that the ICA-stump is longer than expected 
indicating that the vascular tie in many cases are not so high/central. 
Finally, in the present studies (paper III & IV) we retrospectively evaluated surgical reports. 
Two of the authors of paper III and IV read almost 1900 surgical reports describing right 
sided hemicolectomy. This has the advantage of looking into individual patients surgical 
procedures, hopefully evaluating the surgical procedure only. We found that it was often 
difficult to determine from a surgical report whether CME has been performed or not. “CME” 
or “no CME” was almost never stated in the report. Also, we noted that many surgical reports 
were of low quality. Vital information was often missing, unnecessary information was taking 
up large amount of text and it was in some cases unfortunately apparent that the surgeon’s 
anatomical knowledge was unsatisfactory, alternatively there were an inability to describe the 
anatomy. Another drawback of this method is that the reading of a surgical report is done by a 
human and the assessment is therefore inevitable colored by the reader’s subjective 
impression, even though we used a checklist as described in paper III and IV. This might 
introduce misclassification as a bias, however probably non-differential since the surgical 
reports were blinded. It is our impression that we might have judged the reports too strict, 
thereby classifying too few as CME. This would bias the effects of CME towards no 
difference and since our results in both paper III and IV points towards positive effects of 
CME, this may not be a problem, in this case. 
There are no studies on pathology-specimen, assessing whether CME has been done or not. 
West et al has studied specimens from a CME-center (Erlangen) and compared them with 
specimens from a non-CME-center (Leeds). They found that the specimens from Erlangen 
contained more lymph nodes and that the surgical dissection was carried out in the mesocolic 
plane to a greater extent in Erlangen. This study, however, did not have as an aim to 
determine if CME had been done or not, judging from the specimen, and the pathologists 
evaluating the specimens were not blinded to whether the specimen was a CME-specimen or 
not176. From Denmark there are also a studies comparing time-periods and pathological 
specimens showing that educational efforts resulted in specimens with a higher proportion of 
dissection along the mesocolic plane and removal of more mesentery and a greater lymph 
node yield181, 182.  
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Laparoscopic CME 
It has been disputed whether it is possible to do a CME laparoscopically. There are no studies 
comparing long term outcome after open and laparoscopic CME. However there are studies 
on feasibility regarding laparoscopic D3 and CME surgery183, 184. Regarding specimen 
parameters Gouvas et al found in a non-randomized study of 90 laparoscopic and open 
operations no significant differences in distance between bowel wall or number of lymph 
nodes in the specimens185. In contrary West et al showed, when comparing specimens from 
open and laparoscopic CME, a lower number of lymph nodes after laparoscopic CME but a 
similar rate of mesocolic plane dissection186.  
In our paper IV, 144 patients (12.3 %) of the examined operations were laparoscopically 
performed. Of these, 19 (13.2 %) were classed as CME, 32 (22.2 %) were classed as uncertain 
CME and 93 (64.6 %) as no CME. 
Lymph node yield 
Lymph node yield has been shown to be of importance in colon cancer surgery135, 138. In paper 
I we showed that the lymph node yield increased over time in the region, coincident in time 
with introduction of CME. Also in paper IV, CME or “CME uncertain” was associated with a 
higher number of analyzed lymph nodes compared to ”no CME”. 
Bertelsen compared two time-periods in one hospital before and after CME-implementation 
and showed that the mean number of analyzed lymph nodes increased from already high 24.5 
to 26.7 (p=0.009)187. When comparing CME-hospital and non-CME-hospitals, there were a 
median of 34 vs. 19 (p<0.001) lymph nodes in favor of the CME-hospital188. Storli et al in 
Norway noted no statistical significant difference in lymph node yield between a CME 
hospital and non-CME hospitals177. In the comparison of specimens between Erlangen and 
Leeds, there were more lymph nodes in the CME-specimens from Erlangen, median 30 vs. 18 
(p<0.001)176. In a patient series in Erlangen the proportion of colon cancer specimens where 
the pathologist examined at least 12 lymph nodes, rose from 85% to 100% over a period of 
three decades189. 
Is CME associated with short term adverse events? 
In paper III we found that CME is not associated with short term, serious adverse events 
manifesting in death or emergency re-operation. Especially in high-volume hospitals and in 
the later part of the study period this was more salient. 
Bertelsen et al found that CME was associated with more intra-operative organ injuries in the 
CME group. This was mainly because of injuries to other parts of the colon, the spleen and 
the SMV. Also pulmonary failure and sepsis was more common in the CME group. There 
were no statistical significant differences in 30- or 90-day mortality between CME-hospital 
and non-CME-hospitals in this Danish study. Any difference in re-laparotomy is not stated 
but there were no difference in surgical complications Clavien-Dindo grade IIIb175. In our 
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paper III we chose not to include specified surgical or non-surgical adverse as an outcome 
since it is underreported in the SCRCR154. Storli reported a lower (not significant) short term 
mortality after CME, compared to the patients operated in the non-CME hospitals177. 
Another Norwegian study has investigated whether dissection of D3 lymph nodes may cause 
damage to the superior mesenteric autonomous nerve plexus, causing diarrhea. They found an 
increased number of bowel movements among patients operated with a D3 resection, 
although not affecting quality of life190. 
CME and long term outcome 
In paper II we found that both crude OS and DFS among resected patients in stage I-III was 
significantly higher after CME had been discussed, taught and, to an unknown extent, 
implemented in the region. In paper IV we found that patients operated for right sided colon 
cancer where the surgical report contained essential steps of CME surgery had a survival 
benefit. 
In accordance with our findings, Bertelsen found that four year DFS was 85.8% at a CME 
hospital and 75.9% in three other hospitals not performing CME. This figures were confirmed 
when the population was compared with propensity score matching. In this study the positive 
effect of CME was most prominent in stage I-II188. In contrary in our paper II, the survival 
benefit was more pronounced in stage III in the later time period after the introduction of the 
CME concept. Storli in Norway reports a three year DFS of 82.1 versus 74.3 % (p = 0.026) 
when one CME hospital was compared to two non-CME hospitals. In this study only patients 
in stage I-II were included177. Bokey et al reports a 5-year OS of 76.2% and a cancer specific 
survival of 89.8%, among radically resected patients in stage I-III161. In an update of the 
Erlangen-results in 2016, a gradually increasing (statistically not significant) OS from 72.8 to 
78.3%, and a cancer related survival rising from 78.9 to 90.6 (p<0.001) from 1978 to 2009 
were reported. Consistent with our paper II, improvement over time was in Erlangen most 
pronounced in pTNM stage III189. Hohenberger and Bokey both reports excellent outcomes 
although these are studies from single centers. In a study by Adamina et al 52 consecutive 
patients with right sided colon cancer underwent laparoscopic CME and there were no local 
recurrences and four (7.7 %) distant metastases after 38 months of follow up191. 
These studies support CME but cannot define what specific components of CME surgery that 
is crucial for the observed improved oncological outcome. 
Why do CME seem to be associated with better long term outcome? 
One central part of CME is the central vascular ligation with the aim of a greater lymph node 
yield. This has been addressed in several publications. A very large Japanese population 
based study included patients operated for T3 and T4 colorectal cancer and compared D3 to 
D2 operations. On purpose they included patients operated before 1995 in an attempt to avoid 
confounding of newer chemotherapy agents. After propensity score matching they found a 
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significant benefit for OS for D3-operation (HR =0.81 (95 % CI: 0.74-0.89)192. The Danish 
study mentioned above noted a negative correlation (although statistically not significant) 
between the length of the remaining vascular pedicle in vivo and the number of lymph nodes 
in the specimen178. West et al compared specimens from two centres in Japan and one in 
Germany (Erlangen) and found that the Japanese specimens showed a smaller lymph node 
yield and where shorter in terms of bowel length, although there was no difference in the 
distance from the bowel wall to the vascular tie and no difference in the number of metastatic 
lymph nodes67. This implicates that the width of the mesenteric specimen (and the length of 
the resected bowel) plays a role in terms of lymph node numerical but not obviously in 
oncological outcome. A Swedish study supports this finding by showing no survival benefit 
of longer bowel resections, however without data on the length of the vascular pedicle193. 
The second central part of CME is dissection along embryonal planes. Two studies have 
investigated the relationship between mesocolic plane dissection and outcome. West et al 
showed a better outcome in pTNM-stage III patients where dissection had been in the 
mesocolic plane compared to the muscularis propria plane (HR=0.50, 95% CI:0.26-0.98)194. 
An Italian study showed similar results and also that respecting the mesocolic plane resulted 
in a higher frequency of R0 resections195. However, neither of these studies has adjusted for 
microscopically radical resection in a multivariable analysis.  
In conclusion, two papers in this thesis, II and IV, imply that CME is associated with 
advantages regarding long term survival. This is supported by a number of other studies. It is 
not clear which specific part of the surgical concept included in CME that is responsible for 
the observed better oncological outcome. Consistent with the studies mentioned above, the 
CVL may entail better staging and resection of central metastatic lymph nodes, which may 
benefit some patients with advanced tumors. Furthermore, in our paper IV there were less 
missing data on preoperative radiology in the CME group, maybe suggesting a more thorough 
workup. This may be an indication that CME is included in a more thorough and dedicated 
care for colon cancer patients, resulting in overall improved results. Even so, there are reasons 
to believe that precise, meticulous surgery is important in oncologic surgery. 
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CONCLUSIONS     
Overall conclusions 
Prognosis for patients operated for right sided colon cancer in Stockholm has improved the 
last two decades. CME is feasible, safe and associated with good long term outcome and may 
be part of the improved results. 
Specific conclusions 
Between 1996 and 2009, lymph node yield in surgery for right sided colon cancer increased 
together with a decrease in MI. During the same period the proportion of emergency tumor 
resections decreased. 
After the introduction of SCCP, the prognosis for patients diagnosed with right sided colon 
cancer was improved. 
CME for right sided colon cancer does not seem to be associated with serious short term 
adverse events leading to death or emergency re-operation. 
Patients with right sided colon cancer operated with CME had a better long term oncological 
outcome. 
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FUTURE PERSPECTIVES 
The papers included in this thesis, and other papers, shows advantages with CME. 
Simultaneously, in Stockholm and in Sweden, a low proportion of patients have been 
operated with minimally invasive methods for colon cancer. It is likely that this proportion 
will increase the coming years. As described above, laparoscopic CME is feasible. One 
dimension lacking in laparoscopic surgery is the possibility to palpate central part s of the 
colonic mesentery and thereby judging the eventuality of lymph node metastases. On the 
other hand an advantage with laparoscopic surgery is that many operations, depending on 
local routines, are recorded and possible to evaluate afterwards. This would render another 
dimension in evaluating whether CME has been conducted or not. 
Another aspect that warrants studying is the connection between pre-operative staging and the 
selection of patients for CME. As mentioned above, T1 and T2 tumors carry a low risk of 
central, D3, metastases. CT cannot optimally foresee the T-stage of the tumors, neither lymph 
node metastases. Is MRI a future alternative in the preoperative evaluation of colon cancer 
patients? 
Already today many parameters are prospectively recorded in the patients file and in the 
SCRCR. Perhaps prospective registration of CME or not CME could be made mandatory in 
the surgical report to facilitate future research on the topic. 
Post-operative morbidity and mortality is high in surgery for CRC. Part of the explanation is 
probably that about 50% of the patients are older than 70 years. In one hospital in Stockholm 
there is, since some years ago, a project on peri-operative care of patients that are old and/or 
co-morbid. This focuses on identifying high risk patients before surgery for CRC. High risk 
patients are identified either by a web-based risk-calculator or by the anesthesiologist at a pre-
op visit. In high risk patients, not only peri-operative monitoring and fluid-management is 
included but also meticulous care the first days post-operatively. Preliminary this has 
improved short-term results among old and co-morbid patients but warrants further studies. 
Since complications (such as AL) has impact both on short- and long term outcome in CRC-
surgery, it is probably an area where studies are warranted to further improve the prognosis 
for patients with CRC. 
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POPULÄRVETENSKAPLIG 
SAMMANFATTNING PÅ SVENSKA 
Complete Mesocolic Excision (CME) är en ny operationsmetod för tjocktarmscancer där man 
följer anatomiska, embryonala skikt och bevarar ytan av tjocktarmsmesenteriet intakt samt att 
man delar till- och frånförande blodkärl mycket centralt nära avgångar från stora 
kropsspulsådern. Syftet är att minska risken för spridning av tumörceller i bukhålan och att ta 
bort och analysera ett stort antal lymfkörtlar, vilket är viktigt för prognos och för beslut om 
eventuell behandling med cellgifter. Det finns inga randomiserande studier som jämfört CME 
mot traditionell kirurgi. Det finns dock enskilda centra som praktiserat CME och uppvisat 
mycket goda resultat. Den nya operationsmetoden CME introducerades i Stockholm 2004. 
Det har funnits farhågor att CME skall leda till allvarliga komplikationer på kort sikt då 
operationsmetoden innebär att man dissekerar nära bukspottkörteln, tolvfingertarmen samt 
stora, centrala blodkärl. Syftet med detta avhandlingsprojekt var att utvärdera introduktionen 
av CME och dess effekt på kort och lång sikt för patienter med tjocktarmscancer. 
I delarbete 1 visade vi att antalet lymfkörtlar analyserade av patolog efter kirurgi för 
högersidig tjocktarmscancer ökade mellan åren 1996 och 2009. 
I delarbete 2 visade vi en bättre överlenad hos patienter som diagnosticerats med högersidig 
tjocktarmscancer 2006-2008 jämfört med 2001-2003. 
I delarbete 3 undersökte vi om CME ledde till allvarliga komplikationer på kort sikt, 
manifesterade i dödsfall inom 90 dagar efter operationen eller akut omoperation. Detta 
utvärderades i form av en s.k. fall-kontroll studie där CME utgjorde exponering och död eller 
akut omoperation utgjorde utfallet. Huruvida patienter exponerats för CME eller inte 
bedömdes från operationsberättelser. Vi fann att 14.8% av fallen opererats enligt CME 
jämfört med 19.5% av kontrollerna, vilket tolkas som att CME inte ökade risken för akut om-
operation eller död på kort sikt.  
I delarbete 4 bedömdes operationsberättelser hos alla patienter som opererats för högersidig 
tjocktarmscancer i Stockholm under åren 2008-2012. 30.5% av patienterna bedömdes ha 
opererats enligt CME. Efter fem års uppföljning var återfallsfri överlevnad i den gruppen som 
opererats enligt CME 73.6% jämfört med 65.8% i gruppen som bedömts inte opererats enligt 
CME. Sammanfattningsvis visar denna avhandling att CME verkar vara associerat med 
förbättrad långtidsöverlevnad och inte verkar vara behäftad med några uppenbara nackdelar 
på kort sikt. 
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